期刊文献+

95例新型抗肿瘤药物不良反应分析

Analysis of Adverse Reactions of 95 Cases of Novel Antineoplastic Drugs
下载PDF
导出
摘要 目的 分析我院上报的新型抗肿瘤药物药品不良反应(ADR)的特点和发生规律,为ADR监测和合理用药提供参考。方法 收集我院2020年1月~2023年12月上报的95例新型抗肿瘤药物ADR,对患者基本情况、报告类型、发生时间、给药途径、涉及药品、ADR累及系统、转归情况等方面进行分析。结果 95例ADR中,男女比例为1∶0.83;≥50岁人群超过80%;给药途径以静脉滴注为主。ADR涉及28种药品,新的和严重的ADR 60例(63.16%);程序性死亡蛋白1(PD-1)抑制剂占比最高(31例,32.63%);其中卡瑞利珠单抗例数最多(11例);ADR可累及多个系统,皮肤及其附件损害最常见(32例,33.68%)。结论 临床应重视新型抗肿瘤药物ADR监测,关注此类药物新的和严重的ADR,加强患者的用药宣教,确保治疗的安全性和持续性。 OBJECTIVE To analyze the characteristics and occurrence rules of adverse drug reactions(ADRs) of new antineoplastic drugs reported in our hospital,and to provide reference for ADR monitoring and rational drug use.METHODS A total of 95 cases of ADR of new anti-tumor drugs reported by our hospital from January 2020 to December 2023 were collected,and the basic information of patients,report type,occurrence time,route of administration,drugs involved,ADR involvement system,and prognosis were analyzed.RESULTS Among the 95 ADRs,the male-to-female ratio was 1∶083;and more than 80% of the ≥ were 50 years old;and the route of administration was intravenous infusion.ADRs involved 28 drugs,with 60 new and severe ADRs(63.16%)prog;rammed death protein 1(PD-1) inhibitors accounted for the highest proportion(31 cases,32.63%);and camrelizumab having the largest number(11 cases);ADR could involve multiple systems,and skin and its appendages were the most common(32 cases,33.68%).CONCLUSION Clinical attention should be paid to the monitoring of ADR of new anti-tumor drugs,pay attention to the new and severe ADR of such drugs,strengthen the drug education of patients,and ensure the safety and sustainability of treatment.
作者 巫建群 邓晓莉 WU Jian-qun;DENG Xiao-li(Department of Pharmacy,Sanming Second Hospital,Yongan 366000,China)
出处 《海峡药学》 2024年第11期114-117,共4页 Strait Pharmaceutical Journal
关键词 新型抗肿瘤药物 药品不良反应 合理用药 药物警戒 New antineoplastic drugs Adverse drug reactions Rational use of drugs Pharmacovigilance
  • 引文网络
  • 相关文献

参考文献9

二级参考文献50

共引文献75

;
使用帮助 返回顶部